Spyre Therapeutics, Inc. announced positive interim Phase 1 results for its two next-generation TL1A antibody programs, SPY002 and SPY072. Both candidates were well tolerated, exhibited pharmacokinetic profiles supporting quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up, demonstrating a half-life of approximately 75 days, more than three-fold greater than first-generation anti-TL1A antibodies.
Building on these results, Spyre initiated its SKYLINE-UC platform study in May 2025, which will evaluate SPY001, SPY002, SPY003, and their combinations in ulcerative colitis. The company also unveiled the SKYWAY-RD basket study for SPY072, targeting rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), with initiation expected in the third quarter of 2025.
These clinical advancements are expected to deliver 9 proof-of-concept readouts across inflammatory bowel disease and rheumatologic conditions in 2026 and 2027. Spyre reported a cash runway into the second half of 2028, indicating strong financial backing for its extensive clinical development plans.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.